Goldman Sachs Downgrades Mindray Medical (MR) to Neutral
More News related to MR
- Mindray Medical (MR) Posts Q3 EPS of $0.38, Tops by 11c
- Mindray Medical (MR) Tops Q3 EPS by 6c; Revs Light
- Mindray Announces Third Quarter 2009 Financial Results
- Mindray Medical (MR) Reports Q3 Adj-EPS of $0.33, Beats by 6c
- Trading Radar for 11/09: Dish Network (DISH), Rockwell (ROK), Priceline.com (PCLN), MBIA (MBI), Ticketmaster (TKTM) Report
More News related to Downgrades
- Sidoti & Co Initiates Coverage on Stratasys (SSYS) with a Neutral
- ThinkEquity Initiates Coverage on Sourcefire (FIRE) with a Buy
- Raymond James Initiates Coverage on Knight Capital (NITE) with a Market Perform
- Raymond James Initiates Coverage on International Game Technology (IGT) with a Market Perform
- Thomas Weisel Initiates Coverage on UQM Technologies (UQM) with an Overweight
Goldman Sachs downgrades Mindray Medical International Limited (NYSE: MR) from Buy to Neutral.
Mindray Medical International Limited, through its subsidiary, Shenzhen Mindray Bio-Medical Electronics Co., Ltd., develops, manufactures, and markets medical devices worldwide.
Related Categories
DowngradesStocks Mentioned
-2.08Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
